Radioactive drug safety tracked for years in rare cancer patients

NCT ID NCT05017662

Completed Knowledge-focused Sponsor: Ariceum Therapeutics GmbH Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study follows 20 people with neuroendocrine tumors who previously received a radioactive drug called 177Lu-satoreotide tetraxetan. Researchers check for long-term side effects, including new cancers, every 3 months for up to 5 years. The goal is to understand the drug's safety over time, not to test if it works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 177Lu-satoreotide tetraxetan (a radioactive drug)
What this could lead to: If successful, this study will provide crucial safety data that could support the future use of this treatment for neuroendocrine tumors.
What could go wrong: This is a small, observational follow-up study with only 20 participants, so results may not apply to all patients. It does not test whether the treatment works, only its long-term safety.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neuroendocrine neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEUROENDOCRINE TUMORS

Contacts and locations

Locations

Aarhus University Hospital

Aarhus, 8200, Denmark
Hôtel Dieu de Nantes

Nantes, 44093 Cedex 1, France
Medical University of Vienna

Vienna, 1090, Austria
Peter Maccallum Cancer Center

Melbourne, 3002, Australia
Ramsay Hollywood Private Hospital

Perth, 6009, Australia
Royal Free Hospital London

London, NW3 2QG, United Kingdom
University Hospital Basel

Basel, 4031, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.